



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 16 April 2018 (#12)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

**Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)**

## 1. Next-Generation Biologics for Sustained HIV Remission (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-18-017\)](#)

**Type:** R01

**Application Due Date:** July 27, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications that support research on and early development of next-generation biologics with the goal of inducing sustained HIV remission.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$2,250,000 to fund 4-6 awards. Application budgets are limited to \$500,000 in direct costs per year. Requested budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Development of a virtual bioequivalence trial simulation platform that integrates population pharmacokinetic modeling algorithms into physiologically-based pharmacokinetic models

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-FD-18-018\)](#)

**Type:** U01

**Application Due Date:** June 20, 2018, by 11:59 PM Eastern Time.

**Funding Opportunity Announcement:** The purpose of this project is to develop and implement a virtual bioequivalence trial simulation platform that can be used to perform population-based statistical analysis in complex and computationally intensive physiologically based pharmacokinetic (PBPK) models developed to describe the absorption, distribution and elimination of active pharmaceutical ingredients formulated in complex and non-complex dosage forms administered via oral or non-oral routes. The developed virtual bioequivalence trial simulation platform will be used to generate predictions on the in vivo drug product performance, to perform bioequivalence assessments between brand name and generic drug products and to inform regulatory decisions relating to generic drug development.

**Budget:** FDA/Center for Drug Evaluation and Research intends to fund up to \$600,000, for fiscal year 2018 in support of this grant program. It is anticipated that up to two (2) awards will be made, not to exceed \$300,000 in total costs (direct plus indirect), per year, per award. The scope of the proposed project should determine the project period. The maximum project period is three (3) years.

## 3. Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-753\)](#)

**Type:** R01

**Application Due Date:** [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

## 4. Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-754\)](#)

**Type:** R21

**Application Due Date:** [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Grant (R21) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing recent (within the first 12 months) from chronic HIV infections.

**Budget:** The combined direct costs budget for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)